Bone metastases from liver cancer: symptoms, treatment, prognosis, and what to do if you experience pain

Bone metastases in liver cancer mean that cells from the primary liver tumor have spread beyond the liver and formed secondary lesions in bone tissue. In the case of hepatocellular carcinoma, the most common primary liver cancer, confirmed bone metastases correspond to the M1 category and stage IVB according to the TNM system. In patients with normal liver function and generally good general condition, extrahepatic metastases are usually classified as advanced BCLC stage C, for which systemic antitumor therapy is the mainstay of treatment. [1]

The bone lesions are not primary bone cancer. They are hepatocellular carcinoma cells, so systemic treatment is chosen according to the guidelines for HCC. At the same time, bone metastases themselves sometimes require separate local treatment—primarily radiation therapy, and if there is a risk of fracture or spinal cord compression, surgery may be necessary. [2]

Spinal metastases are especially serious. New severe back pain, accompanied by weakness or numbness in the legs, difficulty walking, urinary retention, or loss of bladder or bowel control, is a reason to seek immediate emergency medical attention. These symptoms may indicate spinal cord compression; without prompt treatment, there is a risk of irreversible neurological damage. [3]

What are bone metastases from hepatocellular carcinoma?

Metastasis occurs when hepatocellular carcinoma cells break away from the primary tumor, spread through the bloodstream, and become established in another tissue. In bone, they interfere with the normal bone-renewing system and can accelerate bone destruction. [4]

HCC is characterized primarily by osteolytic metastases—foci in which the bone is destroyed and weakened. They may be accompanied by a soft tissue component extending beyond the bone. Reviews of HCC most often describe involvement of the axial skeleton—the spine, pelvis, and ribs. [5]

This biology explains three of the most significant complications:

• severe bone pain;
• pathological fracture of a weakened bone;
• compression of nerve structures, especially the spinal cord.

Hypercalcemia is also possible - an increase in blood calcium due to increased bone destruction. [6]

How often does liver cancer metastasize to bone?

Bone metastases in HCC are less common than lung metastases, but their incidence varies greatly depending on the patient group being studied.

For example, in a large analysis of the National Cancer Database from 2010–2019, bone metastases at diagnosis were reported in 5,285 of 170,576 patients with HCC—approximately 3.1%. [7]

Completely different figures emerge when analyzing only people with extrahepatic metastatic HCC. In a Memorial Sloan Kettering series of 459 patients with extrahepatic metastases, bone lesions were present or developed in 32.9%. [8]

These figures are not contradictory: the first one applies to all patients with HCC, the second one applies to the already selected group with metastatic disease.

Therefore, a statement like “bones are affected in 30% of all liver cancer patients” would be incorrect.

Where in bone does HCC most often spread?

The most clinically significant site is the spine. The pelvic bones, ribs, long bones of the extremities, and, less commonly, other skeletal areas are also affected. [9]

In one large multicenter series, the spine was the most common site of bone involvement, occurring in approximately 60% of patients with bone metastases. Most lesions were osteolytic in nature. The study dates back to an earlier therapeutic era, so its data are primarily useful for understanding anatomy and complications rather than for modern prognosis. [10]

Metastases can be:

• single;
• multiple;
• limited to one section of the skeleton;
• be combined with metastases in the lungs, lymph nodes, adrenal glands or other organs.

The number of bone lesions is important for prognosis and choice of local treatment, but one confirmed distant metastasis is sufficient for the M1 category. [11]

What stage of liver cancer is present when it has metastasized to the bones?

According to the AJCC/TNM system:

Category	Meaning
M0	There are no distant metastases.
M1	There are distant metastases
IVB	Any T, any N, M1

Bone is explicitly included in the staging system as an example of a distant organ. Therefore, confirmed bone metastasis from hepatocellular carcinoma means stage IVB, regardless of the size of the primary liver tumor. [12]

However, for HCC, TNM staging alone is not enough. Doctors also evaluate liver function and the patient's functional status.

In BCLC 2026, extrahepatic spread is classified as BCLC C if liver function is relatively preserved and the patient maintains an adequate functional status. For this group, systemic therapy becomes the primary approach. [13]

A person with the same anatomical stage IVB, but with severe decompensated cirrhosis, may have completely different treatment options and prognosis.

What are the symptoms of bone metastases?

Pain

Bone pain is the most characteristic symptom. It may initially occur intermittently, intensify at night or with exertion, and then become constant. [14]

In HCC, pain is particularly important because many bone lesions are osteolytic and can significantly damage bone structure.[15]

However, back, rib, or joint pain in a person with HCC does not automatically indicate metastases. More common causes include degenerative, muscular, or traumatic ones.

Alertness is increased by:

• new progressive pain without clear cause;
• pain that does not go away with rest;
• night pain;
• local bone pain;
• combination of pain with known progression of HCC;
• a sudden, sharp increase in pain.

Pathological fracture

Metastasis can weaken the bone so much that a fracture occurs after minor trauma or even normal stress.

The long bones that bear the body's weight, and the vertebrae, are particularly important. Sudden, sharp pain, followed by localized tenderness, may indicate a fracture. [16]

If imaging shows a high risk of fracture of the femur or other major bone, an orthopedic oncologist may recommend prophylactic fixation before a fracture occurs. Radiation therapy is often considered after surgery. [17]

Metastases in the spine

Vertebral metastases deserve special attention not only because of pain.

The tumor may:

1. destroy the vertebral body;
2. cause its pathological fracture;
3. form a soft tissue component;
4. penetrate the spinal canal;
5. compress the spinal cord or nerve roots.

Spinal cord compression is considered an oncological emergency. [18]

When to seek immediate help

If you have a known or suspected spinal lesion, you should not wait for a scheduled appointment if:

• rapidly increasing back or neck pain;
• pain that radiates into one or both legs;
• new weakness in the legs;
• a feeling that your legs “can’t hold you up”;
• gait disturbance;
• numbness in the legs, abdomen, or perineum;
• difficulty urinating;
• loss of control over urine;
• fecal incontinence.

These symptoms are compatible with spinal cord or cauda equina compression and require urgent evaluation.[19]

In its 2024 guideline, ASTRO recommends considering multimodal treatment for confirmed compression. In suitable patients, surgical decompression followed by radiation therapy is preferred over radiation therapy alone; corticosteroid therapy is also used. [20]

Steroids should not be started on your own for ordinary back pain: the indication arises from a specific suspicion of neurological compression and requires a medical evaluation.

Hypercalcemia

When bone tissue is destroyed, calcium can enter the bloodstream. Hypercalcemia can cause:

• severe weakness;
• drowsiness;
• confusion;
• nausea;
• constipation;
• thirst;
• frequent urination;
• disruption of kidney and heart function.

This is a known complication of bone metastases in general, although it does not occur in every patient with HCC. [21]

Severe confusion, sudden deterioration in condition, or dehydration require urgent medical evaluation and laboratory determination of calcium.

How are bone metastases detected in liver cancer?

There is no single, mandatory "bone metastasis test." The testing method chosen depends on the symptoms and location of the suspected lesion.

Can be used:

Study	What is it especially useful for?
X-ray	Fracture, severe destruction of bone
Computed tomography	Bone structure, cortical destruction, surgical planning
Magnetic resonance imaging	Spine, bone marrow, nerves, spinal cord
PET/CT	Metabolically active foci and simultaneous assessment of other organs
Bone scintigraphy	Search for multiple skeletal lesions in certain situations
Biopsy	Confirmation of the origin of an atypical or single lesion

The general capabilities of these methods are confirmed by modern materials on bone metastases. [22]

Should all patients with HCC have a bone scan?

No. Routine bone scan is not generally required for every patient with HCC.

The American Cancer Society points out that bone scanning is not typically performed for liver cancer unless specifically indicated; it is more often considered for bone pain or in some situations of complete staging before potentially definitive treatment.[23]

This is important for the interpretation of the search query: the absence of scintigraphy in initial HCC does not necessarily mean that the workup was incomplete.

If new local pain or suspicion of spinal damage appears, the situation changes and a targeted investigation is required.

Which is better for back pain: CT or MRI?

If the main question is whether there is compression of the spinal cord or nerve structures, magnetic resonance imaging is especially valuable.

She shows:

• bone marrow;
• epidural tumor component;
• spinal cord;
• nerve roots;
• compression ratio.

CT scanning better demonstrates the extent of bone destruction and is often necessary for planning surgical stabilization.

In clinical practice, these studies can therefore complement rather than replace each other.

What is the role of PET/CT specifically in HCC?

Fluorodeoxyglucose PET/CT is not a universal standard for routine initial staging of all patients with HCC. However, it may be useful if bone metastases are suspected.

Small studies of HCC have shown higher sensitivity of FDG-PET/CT for bone metastases compared with scintigraphy, likely in part due to the often osteolytic nature of these lesions. These studies are relatively old and do not allow PET to be considered a mandatory examination for every patient. [24]

The practical choice of method therefore depends on what needs to be determined:

• local cause of pain;
• spinal stability;
• presence of compression;
• prevalence of the metastatic process;
• the nature of the indeterminate bone lesion.

Is a bone metastasis biopsy necessary?

Not always.

If a person has confirmed HCC, a progressive liver tumor, and multiple typical metastatic lesions are detected, the physician may have sufficient clinical confidence without performing a separate bone biopsy.

A biopsy becomes especially useful if:

• the bone lesion is single;
• his appearance is atypical;
• HCC has not been reliably confirmed previously;
• another malignant tumor is possible;
• The diagnosis will significantly change the treatment tactics.

The general principle for bone metastases is to allow biopsy in diagnostically uncertain situations. [25]

How is HCC with bone metastases treated?

Treatment usually consists of two parallel components:

1. systemic treatment of hepatocellular cancer throughout the body;
2. treatment of specific bone lesions and their complications.

These two levels cannot be opposed to each other.

Radiation therapy to the affected vertebra can quickly improve local symptoms, but does not treat invisible metastases elsewhere in the body. Systemic immunotherapy targets the entire disease, but if the vertebra is unstable, separate surgery may be required.

Systemic treatment

Extrahepatic metastases move a patient with normal liver function to BCLC category C, for which BCLC 2026 recommends systemic therapy. [26]

EASL recommends that patients with advanced HCC, Child-Pugh liver function A and ECOG 0-1 be offered combinations containing a PD-1 or PD-L1 inhibitor unless contraindicated.[27]

Modern first-line immune combinations include, depending on the country and availability:

• atezolizumab + bevacizumab;
• tremelimumab + durvalumab;
• nivolumab + ipilimumab;
• in some regions camrelizumab + rivoceranib.

BCLC 2026 includes these regimens among current first-line options and specifically emphasizes that it is incorrect to indirectly compare the results of different studies and declare one regimen as universally “best.” [28]

In the US, the combination of nivolumab and ipilimumab received FDA approval for first-line unresectable or metastatic HCC on April 11, 2025, based on CheckMate-9DW.[29]

In cases of contraindications to immune combinations or in subsequent lines, tyrosine kinase inhibitors and other drugs may be used according to the history of previous treatment, liver function and regulatory indications. [30]

Why is liver function so important?

Even with the same number of bone metastases, two patients may have very different treatment options.

Most registrational studies of modern systemic therapy for HCC have primarily included patients with Child-Pugh A, i.e., relatively preserved liver function. EASL emphasizes that the evidence for decompensated cirrhosis is significantly weaker; systemic treatment should not be automatically prescribed for such patients. [31]

Before choosing a therapy, the following are assessed:

• bilirubin;
• albumen;
• coagulation parameters;
• ascites;
• hepatic encephalopathy;
• Child-Pugh;
• ALBI;
• ECOG;
• tumor load in the liver.

Therefore, with bone metastases, the prognosis is often determined not only by the skeletal lesions, but also by how well the liver itself continues to function.

Radiation therapy for bone metastases

Radiation therapy is one of the main methods of pain control in symptomatic bone metastases.

The updated 2024 ASTRO guidelines strongly recommend external beam radiation therapy for symptomatic relief of bone and spine metastases. The guidelines were developed in consultation with experts from various specialties and are supported by several international professional organizations. [32]

The main goals may be different:

• reduce pain;
• stop local destruction;
• reduce tumor mass around nerve structures;
• treat after surgical stabilization;
• control a separate progressive lesion.

Early HCC-specific studies also showed good palliative effects of irradiation of painful bone metastases, although these studies were conducted before the modern era of immunotherapy.[33]

Do I need to have multiple radiation sessions?

Not necessarily.

ASTRO recognizes several effective regimens for conventional palliative radiotherapy, including both single-dose and multi-day courses. In studies, the pain-relieving effects of different standard regimens were generally comparable, although repeat irradiation is required somewhat more frequently after a single treatment. [34]

The specific scheme is selected by the radiotherapist taking into account:

• localization;
• risk of fracture;
• nerve compression;
• previous irradiation;
• life expectancy;
• general condition;
• the need for surgery.

Therefore, “10 sessions are always better than one” or the opposite statement does not correspond to the modern approach.

What is stereotactic radiation therapy?

Stereotactic radiotherapy allows for the delivery of a more intense dose to a localized area with high precision.

ASTRO 2024 conditionally recommends it over conventional palliative radiation for selected, well-selected patients with good functional status who do not require surgery and who have no neurological symptoms of compression. [35]

This may be of particular interest when:

• a small number of bone metastases;
• good control of the remaining foci;
• isolated progression of one metastasis;
• the need for long-term local control.

However, stereotactic irradiation should not delay urgent decompression in case of neurological deficit.

When is bone surgery needed?

Surgery is not used for every bone metastasis, but primarily when it is necessary to maintain mechanical stability or protect the nervous system.

Main reasons:

• a pathological fracture that has already occurred;
• high probability of fracture of the load-bearing bone;
• spinal instability;
• spinal cord compression;
• the need for decompression of nerve structures.

In cases of high risk of long bone fracture, prophylactic fixation with a metal structure can be performed. This helps prevent a more severe fracture and preserve walking ability. [36]

ASTRO recommends that postoperative radiotherapy be considered after surgery for symptomatic bone metastasis.[37]

Vertebroplasty and kyphoplasty

For some pathological compression fractures of the vertebrae, methods of strengthening the vertebra with bone cement are used - vertebroplasty or balloon kyphoplasty.

They may reduce mechanical pain and improve stability in appropriately selected patients, but do not replace systemic antitumor treatment.[38]

In the presence of an epidural tumor or spinal cord compression, the safety of the nerve structures must first be addressed.

Bisphosphonates and denosumab

For bone metastases from solid tumors, drugs that reduce bone tissue destruction are widely used:

• bisphosphonates, such as zoledronic acid;
• denosumab.

They are able to reduce the risk of bone complications such as fractures, hypercalcemia and the need for additional local interventions. [39]

For HCC, the evidence base for these drugs is significantly weaker than, for example, for breast or prostate cancer. There is no specific contemporary HCC consensus that would require prescribing denosumab or a bisphosphonate to every patient with bone metastasis; a literature review clearly notes the lack of specialized guidelines for HCC with bone metastases. [40]

Therefore, the decision is made individually, taking into account:

• expected benefit;
• kidney function;
• calcium;
• dental condition;
• risk of osteonecrosis of the jaw;
• forecast;
• combinations with other drugs.

Before initiating bone-modifying therapy, it is usually important to address active dental problems, as osteonecrosis of the jaw is a rare but serious complication of such drugs.[41]

Is it possible to remove a single bone metastasis?

Local radical therapy is sometimes discussed, but it is not a standard strategy for most patients.

If there is a single or very limited bone lesion and intrahepatic HCC is well controlled, a multidisciplinary team may consider:

• high-dose stereotactic radiation therapy;
• surgical removal;
• ablative methods;
• combined local treatment.

BCLC 2026 recognizes the heterogeneity of extrahepatic spread and notes that oligometastatic disease may have a different clinical trajectory than multifocal metastatic disease. However, evidence for a universal "radical" strategy for bone oligometastasis in HCC is still insufficient. [42]

Therefore, removal of one lesion does not negate the systemic nature of the disease.

What to do if only one bone metastasis grows during therapy?

This condition is called oligoprogression: most of the tumor remains under control, but one or more foci begin to grow.

EASL allows for local treatment of an isolated area of progression in patients with a sustained response to systemic therapy, while continuing systemic treatment. The level of evidence for this strategy is currently low, so the decision is individualized. [43]

For example, a single enlarging spinal metastasis can sometimes be irradiated without changing effective systemic therapy if the remaining lesions remain stable.

Is it possible to walk and engage in physical activity?

Depends on the stability of the specific bone.

If the metastasis is in a rib or other non-weight-bearing area, restrictions may be minimal.

The situation is completely different with a large osteolytic lesion in:

• femur;
• pelvic bone;
• vertebra.

If the risk of fracture is high, normal weight bearing can be dangerous.

Therefore, if a painful metastasis to a weight-bearing bone occurs, an evaluation by an orthopedist or bone metastasis specialist should be obtained before increasing physical activity.

If new, severe pain occurs when putting weight on the leg, it may be prudent to limit weight bearing until medical evaluation.

How is the response of bone metastases to treatment monitored?

Monitoring a bone lesion is more difficult than measuring a simple metastatic node.

After effective therapy, osteolytic metastases sometimes begin to harden and become sclerotic. This may reflect healing rather than progression.

In contrast, changing only bone density without taking into account:

• symptoms;
• soft tissue component;
• other foci;
• general dynamics of the disease

May be misinterpreted.

CT, magnetic resonance imaging, and sometimes PET and other methods are used for assessment, depending on the clinical question. Recent reviews emphasize that MRI and PET are capable of assessing both the anatomical and functional characteristics of bone lesions. [44]

If the pain has subsided and the tumor in other organs is responding to treatment, one ambiguous bone finding on the image should not automatically be interpreted as the failure of the entire therapy.

Prognosis for liver cancer with bone metastases

Bone metastases indicate an advanced stage of the disease, but there is no universal life expectancy figure for this diagnosis.

Older articles on HCC with bone metastases often report median survival of only a few months. However, many of these series date back to the era before modern immune combinations and included patients with severe liver disease and limited treatment options. Therefore, using these data as a prognosis for a patient treated in 2026 is inappropriate. [45]

The current BCLC 2026 estimates the median overall survival for the entire BCLC C group after effective first therapy at approximately 2 years. This is not a prognosis specifically for bone metastases, but a benchmark for patients with advanced HCC, preserved liver function, and the ability to receive modern treatment. [46]

Therefore, two phrases:

• “with bone metastases they live for several months”;
• "BCLC C today has a median of about two years."

They may come from real studies, but they describe different eras and different groups of patients.

What does SEER show?

According to current SEER data for 2016-2022, the five-year relative survival rate for the distant liver and intrahepatic bile duct cancer category is approximately 3.6%. [47]

But this figure has several serious limitations:

• combines liver cancer and intrahepatic bile duct cancer;
• does not distinguish HCC separately;
• does not highlight bone metastases;
• does not take into account the modern specific treatment regimen;
• unites patients with different liver functions.

SEER explicitly warns that large group statistics do not predict individual patient outcomes.[48]

What most influences an individual's prognosis?

Liver function

In HCC it is of extreme importance.

A person with Child-Pugh A, normal bilirubin, and no ascites is able to receive much more consistent anticancer treatment than a patient with decompensated cirrhosis.

BCLC emphasizes that the prognosis of HCC is determined not only by tumor burden but also by liver function. [49]

The state of the primary tumor in the liver

Even with bone metastases, the tumor load inside the liver itself sometimes remains a direct threat.

Large multiple tumors or vascular invasion may lead to deterioration of organ function faster than a bone lesion.

Number of metastatic organs

An isolated lesion of one bone is clinically different from multiple foci simultaneously in the bones, lungs, lymph nodes and other organs.

Number of bone metastases

A single stable lesion and multiple dissemination throughout the spine, pelvis, and long bones require different strategies and have different risks of skeletal complications.

ECOG

Functional status determines a person's ability to tolerate systemic therapy and local interventions.

Reply to the first line

The actual dynamics after the start of treatment gradually become more informative than the initial statistical figure.

If intrahepatic tumor and bone metastases are controlled long-term, the individual trajectory may significantly exceed historical medians.

Is it possible to live for several years?

Yes, this is possible, especially with preserved liver function and a good response to modern systemic therapy.

BCLC 2026 gives a median target of approximately two years after an effective first line for advanced stage disease in general, and median by definition means that a proportion of patients survive beyond this point. [50]

However, the presence of bone metastases indicates a systemic disease and increases the risk of complications, so it is impossible to transfer this figure to a specific patient without information on:

• Child-Pugh/ALBI;
• ECOG;
• the volume of HCC in the liver;
• vascular invasion;
• other metastases;
• treatment;
• response to treatment.

Is it possible to completely cure the disease?

In typical HCC with confirmed bone metastases, standard therapy is usually aimed at long-term disease control, prolonging survival, and preventing complications, rather than at a guaranteed cure.

Metastatic disease is not typically treated with standard liver resection or transplantation because liver removal will not eliminate tumor cells in the bones. The NCI classifies metastatic HCC as a treatment for systemic therapy and radiation therapy rather than standard radical surgery. [51]

Very limited oligometastatic disease remains the subject of individual strategies and research, but does not yet promise a cure after removal of all visible lesions.

What is often misunderstood

"Bone metastases are already bone cancer."

• No. If they originate from HCC, it is metastatic hepatocellular carcinoma.[52]

"Any back pain with HCC is a metastasis."

• No. Pain can be related to osteochondrosis, muscle problems, arthrosis, trauma, and a variety of other causes. However, new, persistent or progressive pain associated with known HCC requires evaluation.

"If a regular X-ray is normal, there is no metastasis."

• No. Small or early bone marrow lesions may be difficult to detect on X-ray. Depending on the situation, the doctor may use MRI, CT, PET, or scintigraphy. [53]

"You should always do a bone scan."

• No. In HCC without bone symptoms, routine testing is not usually required.[54]

"Radiation therapy only treats pain."

• Not only that. In addition to pain relief, it can provide local tumor control and is used after surgery or for compression of nerve structures. [55]

"After radiation therapy, systemic therapy is no longer needed."

• Generally incorrect. Bone metastasis is a manifestation of systemic HCC, so local treatment of a single lesion usually complements, rather than replaces, systemic therapy.[56]

"If there is only one metastasis, it can be removed and the cancer can be considered cured."

• This conclusion has not been proven. Oligometastatic HCC may have a more favorable course, and local methods are sometimes justified, but the systemic nature of the disease remains. [57]

What to do after bone metastasis is detected

It is practically important to solve several problems sequentially.

First, determine whether there is an immediate threat. It is especially important to rule out spinal cord compression and unstable pathological fracture.

Next, determine the extent of the disease. It's important to understand whether the extrahepatic lesion is limited to bone or whether additional metastases are present.

Assess liver function. Without this, it is impossible to choose the right systemic therapy.

Determine the mechanical stability of the affected bone. If metastasis occurs to the femur or spine, consultation with an orthopedic oncologist or spinal surgeon may be necessary.

Discuss radiotherapy for the painful lesion. For symptomatic bone metastases, this is one of the most proven local methods. [58]

In parallel, a systemic strategy for HCC should be determined. In BCLC with preserved liver function, modern immune combinations are the basis of first-line treatment. [59]

What questions to ask an oncologist

1. Is it confirmed that the bone lesion is indeed a HCC metastasis?
2. Is it one or several metastases?
3. Is there any spinal damage?
4. Is there a risk of spinal cord compression?
5. How stable is the affected bone?
6. Is there a risk of pathological fracture?
7. Is magnetic resonance imaging necessary?
8. Do you need to consult an orthopedist or neurosurgeon?
9. Does radiation therapy make sense?
10. What is the BCLC stage?
11. What are Child-Pugh and ALBI?
12. Which systemic therapy is preferred and why?
13. Is a drug that affects bone resorption needed?
14. Is a dental examination required beforehand?
15. When will the next follow-up study be performed?

Key points from experts

María Reig, MD, PhD, is a hepatologist and director of the Hepatic Oncology Unit at Hospital Clínic Barcelona and the Barcelona Clinic Liver Cancer group at IDIBAPS. Her professional work focuses on the prognosis and systemic therapy of hepatocellular carcinoma; she led the preparation of the BCLC 2026 update. [60]

In BCLC 2026, extrahepatic spread, including bone metastases, is classified as advanced BCLC stage C with preserved liver function and adequate performance status. The primary treatment focus for this group is systemic therapy; individual local interventions are considered in addition to, but not instead of, it. [61]

Sara Alcorn, MD, PhD, is a radiation oncologist at the University of Minnesota and vice chair of the ASTRO Bone Metastasis Guideline Update Task Force. Her credentials and role on the task force are supported by the publication and ASTRO materials. [62]

The ASTRO 2024 Guidelines recommend radiotherapy for symptomatic bone metastases and emphasize multimodal treatment for spinal complications: for spinal cord compression in suitable patients, surgical decompression, radiotherapy, and corticosteroids are considered.[63]

Frequently Asked Questions

HCC bone metastasis - what stage is it?

IVB according to TNM, since bone metastasis means M1. [64]

Is this BCLC C?

With extrahepatic metastases, preserved liver function and suitable ECOG - usually yes. [65]

Where do bone metastases most often occur?

The axial skeleton is most often described - especially the spine, pelvis and ribs. [66]

How do bone metastases usually hurt?

The pain may initially be intermittent and nocturnal, later becoming constant and intensifying with exertion. These characteristics are nonspecific and do not in themselves confirm the diagnosis. [67]

How to distinguish metastasis from ordinary back pain?

The only reliable way to determine this is through examination. New, progressive pain with known HCC requires a medical evaluation, especially if neurological symptoms develop.

What to do if you have weakness in your legs?

Seek emergency medical attention, especially if weakness occurs alongside back pain or is accompanied by numbness and difficulty urinating. This could indicate spinal cord compression. [68]

Is it necessary to have an MRI of the spine?

If spinal cord compression or damage to nerve structures is suspected, magnetic resonance imaging is one of the key investigations.

Is radiation therapy always necessary?

No. But in painful bone metastasis, it is one of the main proven methods for local symptom control. [69]

Is it possible to irradiate a bone metastasis in one session?

In some clinical situations, yes. ASTRO recognizes both single-session and multi-session standard regimens of palliative radiotherapy. [70]

If there is a metastasis in the thigh, can I walk?

It depends on the degree of bone destruction. In the case of a large osteolytic lesion, stress can increase the risk of fracture, so an assessment of mechanical stability is necessary.

Can bone metastasis be removed surgically?

Sometimes, primarily when bone stabilization, nerve decompression, or very limited oligometastatic conditions are needed. This is not a standard procedure for every metastasis.

Is denosumab necessary?

It is used to prevent bone complications in metastatic disease from some solid tumors, but the HCC-specific evidence base is limited. The decision is made on an individual basis. [71]

Is it possible to live for several years?

Yes. With current therapy, some BCLC C patients survive for several years. BCLC 2026 provides a median overall survival target of approximately two years after effective initial therapy for all advanced-stage patients, but this is not a specific statistic for bone metastases or an individual prognosis. [72]

Key facts about bone metastases in liver cancer

Confirmed bone metastases from hepatocellular carcinoma indicate stage IVB systemic disease. In the presence of normal liver function, this is usually BCLC C, and the mainstay of therapy is modern systemic treatment for HCC. [73]

At the same time, the bone lesions themselves may require separate intervention. Radiation therapy is effectively used for symptomatic metastases; if a fracture is imminent, an orthopedic evaluation is necessary, and spinal cord compression requires emergency treatment. [74]

For prognosis, it is significantly more important to know not only the presence of bone metastases, but also the liver status, ECOG, tumor volume within the liver, the presence of other metastases, the risk of skeletal complications, and the actual response to initial systemic therapy. Current results should not be judged by old articles from the era when effective immunotherapy for HCC was not yet available. [75]